Release of Inflammatory Mediators by Human Adipose Tissue Is Enhanced in Obesity and Primarily by the Nonfat Cells: A Review by Fain, John N.
Hindawi Publishing Corporation
Mediators of Inﬂammation
Volume 2010, Article ID 513948, 20 pages
doi:10.1155/2010/513948
Review Article
ReleaseofInﬂammatoryMediators byHuman AdiposeTissueIs
EnhancedinObesityandPrimarilybytheNonfatCells:A Review
John N. Fain
Department of Molecular Sciences, University of Tennessee Health Science Center, Memphis, TN 38163, USA
Correspondence should be addressed to John N. Fain, jfain@uthsc.edu
Received 3 November 2009; Revised 27 January 2010; Accepted 23 February 2010
Academic Editor: Giamila Fantuzzi
Copyright © 2010 John N. Fain.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
This paper considers the role of putative adipokines that might be involved in the enhanced inﬂammatory response of human
adipose tissue seen in obesity. Inﬂammatory adipokines [IL-6, IL-10, ACE, TGFβ1, TNFα,I L - 1 β, PAI-1, and IL-8] plus one anti-
inﬂammatory [IL-10] adipokine were identiﬁed whose circulating levels as well as in vitro release by fat are enhanced in obesity
and are primarily released by the nonfat cells of human adipose tissue. In contrast, the circulating levels of leptin and FABP-
4 are also enhanced in obesity and they are primarily released by fat cells of human adipose tissue. The relative expression of
adipokines and other proteins in human omental as compared to subcutaneous adipose tissue as well as their expression in the
nonfat as compared to the fat cells of human omental adipose tissue is also reviewed. The conclusion is that the release of many
inﬂammatory adipokines by adipose tissue is enhanced in obese humans.
1.Introduction
There is increasing evidence that obesity in humans is
associated with low-level inﬂammation [1–6] that is often
accompanied by hypertension and type 2 diabetes. Currently
it is thought that the increase in visceral omental rather than
abdominal subcutaneous adipose tissue best correlates with
measures of insulin resistance [7] and cardiovascular disease
[8–10].However,theamountofvisceralfathasanallometric
relationship with total body fat content [11] which means
that the increases in visceral fat mass seen in obesity reﬂect
the initial ratio of visceral fat to total fat mass as well as the
changes in total fat mass change. Thus during weight loss
or gain there are concurrent changes in the amount of both
subcutaneous and visceral fat.
The distribution of fat between premenopausal men and
women is diﬀerent with women having generalized lipid
deposition as contrasted to men who tend to accumulate
fat in the abdominal region resulting in a socalled “beer
belly”. There are also sex diﬀerences in the ratio of visceral to
abdominal subcutaneous fat mass between men and women
[4]. The visceral fat mass of the women was approximately
50% of the abdominal subcutaneous fat mass while for the
men it was 98% [4].
The measurement of abdominal subcutaneous and
visceral fat mass can be done using either a computed
tomography (CT) or MRI scan. Measurement of total body
fat requires either a DXA scan or a bioelectrical impedance
scale. In contrast, waist circumference is simply measured
and provides as good if not better measure of the health
risks of obesity than the more complex procedures [12, 13].
However, the use of BMI has the advantage of comparing
men and women on the same scale since it is an index of
weight corrected for height.
This review will primarily discuss studies on the eﬀects
of obesity on circulating adipokines, the relative release
of adipokines by the fat cells versus the nonfat cells of
human adipose tissue, the eﬀects of obesity on adipokine
release by explants of human visceral omental adipose tissue,
and the diﬀerences in gene expression between visceral and
subcutaneous fat. The term adipokine, as used in this review,
means any protein released by adipose tissue without regard
to whether it is released by the fat or the other cells (nonfat
cells) found in human adipose tissue.2 Mediators of Inﬂammation
2. Effects of Obesity on Circulating
Levels of Adipokines
At least 24 adipokines have been reported whose circulating
levels are elevated in obese humans (Table 1). Some of these
putative adipokines such as CRP, haptoglobin, and amyloid
A are actually acute phase proteins primarily released by the
liver in response to the mild inﬂammatory response seen in
human obesity. Most of the remaining 21 are inﬂammatory
proteins such as IL-8, PAI-1, MCP-1, IL-6, IL-1Ra, TNFα,
sTNFRII,andIL-18butthesourceoftheelevatedcirculating
levels in obesity is unclear. Their elevations could result from
release by tissues other than fat. In contrast, leptin levels are
elevated in obesity and the current paradigm is that it is
released by fat cells in adipose tissue. However, in mice it has
been shown that activated T cells and other lymphocytes can
also release leptin under inﬂammatory conditions [14, 15].
The circulating levels of zinc-α2-glycoprotein (ZAG)
have been reported to be unaltered in obesity [17], but the
level of ZAG gene expression in human adipose tissue is
reduced in obesity [69, 70]. This illustrates the problem that
changes in circulating levels of adipokines do not necessarily
reﬂect changes in their release by or correlate with their
mRNA levels in adipose tissue. Most of the adipokines are
also cytokines and are released primarily by cells other than
fat cells in human adipose tissue (Figure 1). Furthermore,
circulating levels of all adipokines are also regulated by their
release from other tissues as well as their degradation. For
others such as interleukin 1β (IL-1β) ,n or e p o r t sh a v eb e e n
published indicating that IL-1β is elevated in the circulation
of obese humans. However, IL-1β is an important regulator
of the inﬂammatory response in human adipose tissue. It
may well be a paracrine regulator that acts locally and never
reaches the blood in mild inﬂammatory conditions such as
o b e s i t y .T h es a m em a ya p p l yt oP G E 2, which is the primary
product of the cyclooxygenase-2 (COX-2) enzyme.
Some of the adipokines may actually have anti-inﬂam-
matory eﬀects and circulate at higher levels in obesity as
part of a homeostatic mechanism to counteract the eﬀects
of the inﬂammatory mediators. Probably interleukin 10 (IL-
10) is such a molecule [71] and there is some evidence that
interleukin 6 (IL-6) has dual eﬀects since it has been claimed
that it enhances insulin action in muscle [72]. Interestingly
there is also evidence that administration of a meal enhanced
release of IL-6 by human adipose tissue perfused in situ [73].
It is as yet unclear whether IL-6 is enhancing or inhibiting
insulin action but the traditional view is that IL-6 inhibits
insulin action [74].
While 24 putative adipokines are listed in Table 1 whose
circulating levels are elevated in obesity there are only
two out of 37, adiponectin and glutathione peroxidase 3
(GPX-3), whose circulating levels have been reported to
be lower in human obesity. The current paradigm is that
circulating levels of adiponectin are reduced in obesity [25,
33, 34]. However, the ﬁnding that circulating GPX-3 is also
lower [35], if conﬁrmed, suggests that GPX-3 may also be
important. GPX-3 is unique among the ﬁve known isoforms
of this enzyme since it is the only one that is secreted
by cells [75]. It is a selenocysteine-containing protein with
0
25
50
75
100
−5 −2.502 .557 .5
mRNA in fat cells as compared to nonfat cells
at start of incubation
R
e
l
e
a
s
e
b
y
f
a
t
c
e
l
l
s
o
v
e
r
4
8
h
a
s
p
e
r
c
e
n
t
a
g
e
o
f
r
e
l
e
a
s
e
b
y
f
a
t
c
e
l
l
s
+
n
o
n
f
a
t
c
e
l
l
s
Adipsin
GPX-3
ZAG Adiponectin
Amyloid
LPL
Leptin
FABP4 Hp NGF
Visfatin
r = 0.8a n dP ≤ .0001
Figure 1: The correlation between releases of 30 adipokines over
48 hours incubation by fat cells isolated from human adipose tissue
as compared to gene expression of these adipokines at the start of
the incubation. The release data are from Table 1 and expressed as
release by fat cells as % of that by fat cells plus nonfat cells over 48
hours. The data for mRNA are derived from those shown in Table 2
except that they are plotted as the ΔCp for the diﬀerence between
mRNA in fat cells and nonfat cells instead of the ratios, which are
derived from the ΔCp values. Data are not included for resistin,
CRP and IL-18 since release by fat cells was below the sensitivity
of the assays and mRNA was not measured for MIF, HGF, VEGF,
and VCAM-1.
antioxidant properties. The circulating levels of GPX-3 and
selenium have also been reported to be lower in patients with
coronary artery disease than in age-matched controls [76].
3.The RelativeReleaseofAdipokinesby
the Nonfat versusthe Fat Cells of Human
Adipose Tissue
It has often been assumed that release of an adipokine by
adipose tissue is due to the fat cells. This originated with
the ﬁnding by Rodbell [77] that lipoprotein lipase [LPL]
is localized in the fat cells of rat adipose tissue. It was
in order to solve the problem of the localization of LPL
that Rodbell [78] developed the collagenase procedure for
separationofinsulin-responsivefatcellsfromthenonfatcells
in rat adipose tissue. However, Cleland et al. [79] found that
most of the aromatase activity in human adipose tissue, that
is responsible for estrogen formation from androstenedione,
was localized in the nonfat cells and most of the IL-6 release
by human adipose tissue was by the nonfat cells [80]. Fain
et al. [62] subsequently reported on the relative release of
11 adipokines by the nonfat as compared to the fat cells
of human omental and abdominal subcutaneous adipose
tissue during an in vitro incubation. Leptin was found to be
released exclusively by the fat cells, while TNFα,h e p a t o c y t e
growth factor (HGF), IL-10, IL-1β,P G E 2,I L - 6 ,v a s c u l a r
endothelial growth factor (VEGF) and interleukin 8 (IL-8)
were primarily released by the nonfat cells.Mediators of Inﬂammation 3
Table 1: Comparison of release of 37 adipokines by fat cells as compared to the other cells in human adipose tissue ranked by fat cell release
along with the eﬀect of obesity on their circulating levels in humans.
Adipokine Release by nonfatcells in pmoles/g Release by fatcells in pmoles/g Eﬀect of obesity on circulating levels
FABP-4 590 360 Elevated [16–18]
PGE2 1810∗ 118∗ No data
IL-8 1120∗ 87∗ Elevated[21, 22]
PAI-1 78∗ 18∗ Elevated[19, 23,24]
MCP-1 74∗ 9.2∗ Elevated[4, 20,22,25]
IL-6 66∗ 5.1∗ Elevated[4, 25–31]
Adipsin 26 4.1 Elevated [28, 32]
Adiponectin 6 4.1 Lower[25, 33, 34]
GPX-3 14 3.6 Lower [35]
Leptin 0.1 1.8 Elevated [19, 25,36]
Amyloid A 1.3 1.6 Elevated [19, 32,37]
Migrationinhibitor factor 2.8 1.0 Elevated [38]
Visfatin/PBEF/Nampt 1.0 0.60 No change [39–41]
CD14 1.6 0.56 No change [42]
ZAG 0.7 0.44 No change [17]
Lipocalin-2 5.4 0.27 No change [42, 43]
Cathepsin S 4.4 0.26 Elevated [44]
RANTES 2.1 0.21 No change [42]b u ts e e[ 25]
IL-1Ra 4.1 0.14 Elevated [36]
Osteoprotegerin 0.1 0.12 No change [42, 45]
HGF 2.8 0.11 Elevated [46]
LPL 0.02 0.080 No change [47]
Haptoglobin 0.08 0.060 Elevated [48]
ICAM-1 0.27 0.056 Elevated [4, 29,49]
ACE 0.23 0.017 Elevated [50]
IL-10 0.53 0.020 Elevated [28]
VEGF 0.30 0.020 Elevated [51]
VCAM-1 0.46 0.016 Elevated [29]
IL-1β 0.23 0.013 No data
TNFα 0.22 0.012 Elevated [5, 27,29–31,52]
TGF-β1 0.17 0.009 Elevated [53]
sTNFRII 0.44 0.007 Elevated [5, 18,19,30, 54]
NGF 0.006 0.005 Elevated [55]
VEGFR/sFLT1 0.018 0.002 No change [34]
Resistin 1.8 <0.04 No change [56, 57]
CRP 0.01 <0.002 Elevated [17, 19,20,28, 30,31,49, 58]
IL-18 0.01 <0.002 Elevated [18, 59,60]
Those in “bold” are adipokines whose circulating levels have been reported to be elevated in obesity, “italic” those where the circulating levels are lower in
obesity, and “normal text” where there is either no eﬀect of obesity or published data. The references are to the reports on circulating levels. The asterisks
indicate that the release of these adipokines was almost certainly upregulated over 48 hours. The rate of release for IL-8 over 48 hours extrapolated from
release over the ﬁrst 40 minutes of incubation were 2.2% of those based on the 48 hours release values [61]. The release values for nonfat and fat cells over
48 hours are the averages of subcutaneous and omental adipose tissue from 8 to 12 humans with a BMI of 32 and an equal number with a BMI of 45. These
data are from Fain et al., [62]e x c e p tf o rh a p t o gl o b i n[ 63], resistin [64], MCP-1 [65], TGFβ1[ 66], MIF, Cathepsin S, NGF, IL-1Ra, IL-18 [67], VCAM-1, ACE,
adipsin, sTNFR2 [68], CD14, LPL, OPG, Amyloid A, ZAG, GPX-3, FABP-4, ICAM-1, RANTES, visfatin, lipocalin-1 [42] while CRP and VEGFR/sFLT1 are
from unpublished experiments.
In vitro, the relative release of adipokines by fat cells
as compared to nonfat cells derived from human adipose
tissue over a 48 hours incubation indicates that the highest
release by fat cells was of fatty acid binding protein 4
(FABP-4) followed by IL-8 (Table 1) .T h eh i g hv a l u ef o rI L -
8 release over 48 hours is primarily due to upregulation,
since the rate of release over 48 hours derived from
release during the ﬁrst 40 minutes was only 2% of the 48
hours release value for both fat cell and nonfat cells [61].
Adipokine release was up-regulated to the same extent in
both types of cells of either omental or subcutaneous fat
[61].4 Mediators of Inﬂammation
The question arises as to how well in vitro release of
adipokines over the ﬁrst 48 hours of primary culture by
human fat cells and nonfat cells reﬂects the in vivo situation.
That cannot be determined because it takes a two-hour
digestiontoseparatefatcellfromnonfatcellsandduringthat
time there is upregulation of the mRNAs for inﬂammatory
cytokines such as IL-8 and IL-6 [81]. However, what can
be measured is the level of gene expression in the nonfat
cells versus the fat cells at the start of the incubation
which can be compared to release over 48 hours. These
data are shown in Figure 1 for 30 of the 37 adipokines
showninTable 1.Therewasanexcellentcorrelation(Pearson
correlation coeﬃcient of 0.8) between release of adipokines
over 48 hours by fat cells as % of that by nonfat cells and
the initial ratio of the mRNA for the adipokine in fat cells
versus nonfat cells. The data also demonstrate that leptin
release is exclusively by the fat cells of omental adipose tissue,
which also contained 28-fold more leptin mRNA than the
nonfat cells (Figure 1). Release of LPL was also primarily by
thehumanfatcellsandinagreementwiththe79-foldgreater
amountofitsmRNAfoundinfatcellsascomparedtononfat
cells.
Adiponectin has generally been considered to be an
adipokine released exclusively by fat cells but while the ratio
for mRNA expression in fat cells as compared to nonfat cells
was 42-X the release of adiponectin accounted for only 40%
of total release. Fain et al. [82] suggested that immature fat
cells or other cells in the nonfat cell fractions of human
adipose tissue also release adiponectin. Alternatively, the
release could be due to adiponectin taken up by nonfat cells
in vivo and then released during the 48 hours incubation.
The release of amyloid A by human fat cells as % of that
by nonfat cells was actually higher than that of adiponectin
and its mRNA content in fat cell was 34-fold greater than
that in nonfat cells. However, amyloid, like adiponectin,
release appears to be about the same by nonfat as by fat
cells. While leptin, LPL, amyloid A, and adiponectin are
adipokines predominantly expressed in fat cells at ratios 30
to80-foldgreaterthaninnonfatcells(Figure 1),thequestion
of whether there is appreciable amyloid and adiponectin
synthesis by the nonfat cells of adipose tissue remains to be
established.
There are four other possible candidates for the designa-
tionofadipokinespreferentiallyreleasedbyfatcells,sincethe
ratios of their mRNAs in fat cells to nonfat cells ranged from
5 for FABP-4, 8 for ZAG, and 9 for adipsin/complement D as
well as GPX3. However, release by fat cells accounted for less
than half of their total release.
4. Relative Expressionof 100 Genes in
FatCellsversustheNonfatCellsof
HumanOmental Adipose Tissue
Table 2 shows the relative gene expression in fat cells versus
nonfat cells of 100 proteins, as determined by qRTPCR
[83]. These proteins were chosen because they are important
in inﬂammation or obesity, regulatory proteins or proteins
enriched in fat cells.
Of the proteins whose gene expression is shown in
Table 2 almost one-third (30) were signiﬁcantly enriched in
fat cells (shown in Bold), 29 were distributed equally (shown
in italic) and 41 were signiﬁcantly enriched in nonfat cells
of human omental adipose tissue (shown in normal text).
Thirty of these proteins are the adipokines whose release by
adipose tissue was examined in the studies shown in Table 1
and Figure 1.
Of special interest was the ﬁnding that 11β HSD1, UCP-
2, cyclic AMP phosphodiesterase 3B, AQP7, angiotensino-
gen, GPX-3, the insulin receptor, and NQO1 are preferen-
tially localized in fat cells [83]. Interestingly ZAG, TLR4,
cytochrome C oxidase, Akt2, adrenomedullin, and UCP-1
were also expressed at levels 4 to 8-fold greater in fat cells
than in nonfat cells [Table 2]. The higher expression of ZAG
in human fat cells than in nonfat cells conﬁrms the report by
Bao et al. [84].
An elevated expression in fat cells was seen for both
cytochrome C oxidase, which is a marker for mitochondria,
and Akt2, which is the isoform of Akt involved in insulin-
stimulated glucose uptake into fat cells [85]. The enhanced
expression of the mitochondrial protein UCP-1 in visceral
omental fat cells was unexpected since it is thought of as a
marker for brown fat cells. However, Sacks et al. [86]f o u n d
far higher expression of UCP-1 in visceral epicardial fat as
compared to subcutaneous fat. The increased expression of
cytochrome C oxidase in fat cells as compared to nonfat
cells of omental fat suggests that fat cells are relatively
enriched in mitochondria. Deveaud et al. [87] have shown
that cytochrome C oxidase is enriched in visceral epididymal
fat of rats as compared to subcutaneous inguinal fat.
The circulating levels of adrenomedullin are elevated in
human obesity [88, 89]. Furthermore, adrenomedullin is
secreted by fat cells [90, 91] but it is unclear whether more
adrenomedullinissecretedbyfatcellsthanbythenonfatcells
of human adipose tissue [88–91].
The proteins whose gene expression was predominantly
in the nonfat cells included all the classical inﬂammatory
proteins such as MCP-1, TGFβ1, IL-6, IL-8, COX-2, PAI-1,
IL-1β,I L - 8 ,a n dT N F α (Table 2). Other putative adipokines,
such as vaspin, endothelin-1, omentin/intelectin, lipocalin-
2, RANTES, and visfatin were also enriched in the nonfat
cells. Vaspin is an adipose tissue-derived serpin whose gene
expression in human visceral fat positively correlated with
obesity [92]. Circulating levels of omentin/intelectin are
lower in obesity [93] but the meaning of this is unclear.
The ratio of gene expression in fat cells to nonfat cells
ranged from 0.06 to 128 (Table 2). However, if in vitro
diﬀerentiated human omental adipocytes were compared to
omental preadipocytes the ratios ranged from 0.001 to over
a million for adiponectin [82, 83]. Clearly there is more
expression of fat cell speciﬁc proteins in freshly isolated
nonfat cells than in preadipocytes obtained by culturing
the nonfat cells of human omental fat. This diﬀerence may
be accounted for, in part, by the presence of small fat
cells without enough fat to ﬂoat, since isolated fat cells
are operationally deﬁned as cells containing enough lipid
to ﬂoat in isotonic incubation buﬀer. Another possibility is
incomplete digestion of adipose tissue leaving some fat cellsMediators of Inﬂammation 5
Table 2: Comparison of 100 mRNAs in fat cells as compared to the nonfat cells derived from human omental adipose tissue.
R a t i oo fm R N Ai nf a tc e l l st on o n f a tc e l l s C pv a l u ei nn o n f a tc e l l s
mRNAs signiﬁcantly enriched in fat cells
Perilipin 128 29.3
Hormonesensitivelipase[HSL] 104 32.4
Lipoproteinlipase [LPL] 79 26.5
Adiponectin 42 28.1
Retinolbindingprotein4 [RBP-4] 42 29.4
Adiposetissuetriglyceridelipase[ATGL] 37 35.4
Amyloid proteinA1 34 27.3
Leptin 28 29.2
FAT/CD36 26 25.8
11β-hydroxysteroid dehydrogenase 1 tv1 [11β HSD-1] 18 30.8
PPARγ 15 30.4
Uncoupling protein2 [UCP-2] 14 28.9
Fat speciﬁc protein27/CIDEC 13 26.0
CIDEA 12 27.0
Glutathione peroxidase 3 [GPX-3] 9 27.0
Adipsin/complementD 9 27.9
Zincα2-glycoprotein[ZAG] 8 28.8
Cyclic AMPphosphodiesterase3B 7 27.6
Angiotensinogen 5 34.1
Toll-likereceptor4 [TLR-4] 5 34.8
Fattyacid bindingprotein4[FABP-4] 5 20.2
Cytochromecoxidase 4 28.1
Glycerol channel aquaporin 7 [AQP-7] 4 27.4
Adrenomedullin 4 26.4
Akt2/proteinkinaseB2 4 27.2
Uncoupling protein1 [UCP-1] 4 32.6
NADPH:quinoneoxidoreductase l [NQO-1] 3 27.2
Insulinreceptor tv1 [INSR] 3 27.5
GAPDH 3 26.7
CGI-58/ABHD5 3 26.2
mRNAs present in both nonfat cells and fat cells
Giα2 guanine nucleotide binding protein 2.1 32.0
Osteoprotegerin [OPG] 1.9 31.0
Thrombospondin 1 1.8 24.5
Sodium hydrogen exchanger 1 1.6 28.9
AMPK α2 catalytic subunit 1.5 32.9
Akt/1protein kinase B1 1.5 27.4
Lipin-1 1.5 26.5
Lipin-2 1.5 27.4
Cyclophilin A 1.4 29.0
Caveolin-1 1.4 26.6
MAP3K8/COT1 1.3 26.5
Receptor interacting protein 140 [RIP 140] 1.3 24.6
Haptoglobin 1.0 31.2
SIRT1/sirtuin1 1.0 27.1
CD14 tv1 1.0 26.0
IL-1 Ra 1.0 33.3
Leucine-rich protein PPR [LRP130] 0.87 27.06 Mediators of Inﬂammation
Table 2: Continued.
R a t i oo fm R N Ai nf a tc e l l st on o n f a tc e l l s C pv a l u ei nn o n f a tc e l l s
NFKB1 [p50] 0.81 33.0
β2 adrenergic receptor 0.76 25.8
Hypoxia inducible factor 1α [HIF-1α] 0.71 27.4
CD 68 0.71 24.0
RAB6 0.66 25.0
Peroxisome proliferator activator receptor-γ coactivator 1α [PGC-1] 0.57 30.0
Apelin 0.57 33.1
MAP4K4 tv 2 0.57 29.2
Heme oxygenase-1 [HMOX-1] 0.57 24.4
Renin receptor 0.54 25.8
β1 adrenergic receptor 0.50 27.8
Resistin 0.33 33.6
mRNAs signiﬁcantly enriched in nonfat cells
Endothelial nitric oxide synthase [eNOS] 0.44 30.2
PI-3 kinase catalytic subunit 0.38 27.2
Cathepsin S 0.38 31.4
NFKB p65 0.35 29.2
Mitochondrial superoxide dismutase-2 tv1 [SOD2] 0.35 21.0
T u m o rn e c r o s i sf a c t o r - α receptor 2 [TNFR-2] 0.29 31.2
Nerve growth factor beta polypeptide [NGF] 0.29 31.5
Interleukin 10 [IL-10] 0.25 30.0
Visfatin/PBEF/Nampt 0.25 21.9
PR domain containing 16 [PRDM16] tv1 0.25 31.5
T u m o rn e c r o s i sf a c t o rα [TNFα] 0.25 30.5
Glycogen synthase kinase 3β 0.23 32.0
Interleukin 8 [IL-8] 0.20 23.6
Osteocalcin 0.20 30.2
α1 glycoprotein 0.20 33.8
Complement C-3 0.19 25.9
Interleukin 1β [IL-1β] 0.19 25.7
Prostaglandin D2 synthase [PGDS] 0.18 23.9
Tribbles 3 [TRB3] 0.18 30.6
Plasminogen activator inhibitor 1 [PAI-1] 0.18 27.3
Bone morphogenetic protein 7 [BMP-7] 0.16 31.8
Intercellular adhesion molecule 1 [ICAM-1] 0.16 25.2
Cyclooxygenase 2 [COX-2] 0.15 27.4
RANTES 0.15 30.0
Angiotensin 1 converting enzyme [ACE] 0.15 31.0
Interleukin 6 [IL-6] 0.14 25.0
Endocannabinoid receptor 1 0.14 25.8
Collagen type VI/PBEF1α3 tv1 [COL6-A3] 0.14 29.9
NADPH oxidase p67phox 0.13 30.5
TGFβ-1 0.12 27.3
NADPH oxidase p47phox 0.12 32.4
Lipocalin 2 0.12 33.5
Butyrylcholinesterase 0.11 33.2
Angiotensin II receptor-1 tv1 [AT1R] 0.10 25.7
Omentin/intelectin 0.09 25.0
Monocyte chemoattractant protein 1 [MCP-1] 0.07 23.2
VEGF receptor [VEGFR/FLT1] 0.07 27.8Mediators of Inﬂammation 7
Table 2: Continued.
R a t i oo fm R N Ai nf a tc e l l st on o n f a tc e l l s C pv a l u ei nn o n f a tc e l l s
25-Hydoxyvitamin D3 1α hydroxylase [25D3-1α] 0.06 26.8
Endothelin-1 0.06 27.8
Angiotensin II receptor-2 [AT2R] 0.06 33.1
Vaspin 0.06 28.1
Those in “bold” are the mRNAs signiﬁcantly enriched in fat cells, “italic” those mRNAs present in both nonfat cells and fat cells to the same extent, and
“normal text” those mRNAs signiﬁcantly enriched in nonfat cells. The data are based on quantitative PCR analysis of mRNA expression [14, 82, 83]. The
ratios were derived from the log2ΔΔCp of the ΔCp (crossing point) for each mRNA, except cyclophilin, of the nonfat cells (pooled undigested tissue + SV
fractions) obtained by collagenase digestion of human omental adipose tissue subtracted from the ΔCp values of fat cells isolated from the same tissue. The
ratio for cyclophilin is based on log2 of the ΔCp values for cyclophilin. A ratio above 1 means that the amount of mRNA is greater in the fat cells than in the
nonfat cells. The values are shown as the means ± SEM of 4 to 21 paired experiments comparing nonfat cells to fat cells derived from the same individual.
Tv1 or 2 stands for transcript variant 1 or 2. The data are from Fain et al. [82, 83] or from unpublished data.
entrapped in the undigested tissue matrix. However, if this
is the case these cells secrete very little leptin since its release
by the nonfat cell fraction is less than 5% of that by isolated
fat cells (Figure 1) and we could ﬁnd no detectable fat in the
nonfat cells [67].
One problem in comparing gene distribution between
fat and nonfat cells is the possibility of preferential lysis of
extremely large fat cells during the collagenase digestion of
fat from extremely obese humans. The isolation of human
fat cells is an art requiring particular batches of collagenase
for optimal yield of responsive cells, gentle incubation
conditions and an optimal ratio of collagenase to tissue
[62, 67]. Fain et al. [67] calculated that there was a 23%
greater loss of fat cells during digestion than of nonfat cells
during the digestion of fat from extremely obese humans.
The fat cells lost during digestion may well be the largest fat
cells that release more inﬂammatory adipokines and leptin
than the smaller cells. A further problem is the up-regulation
of inﬂammatory response genes during the 2 hours required
for collagenase digestion but this aﬀects both fat cells and
nonfat cells to the same extent [61] and thus has minimal
eﬀectsontheratiosofmRNAexpressioninfattononfatcells.
5. Comparison of mRNA Expression in
IsolatedOmental FatCells versusInVitro
Differentiated Adipocytes
Many studies on the relative gene expression of proteins in
fatcellshaveutilizedadipocytesdiﬀerentiatedinvitrosuchas
murine3T3L1cells,butfarfewerstudieshaveappearedusing
humancelllines.Thetermfatcellsisoperationallydeﬁnedas
those cells that ﬂoat and are isolated by collagenase digestion
of human omental adipose tissue from women undergoing
bariatric surgery. Adipocytes are those fat cells derived
from the adipose tissue of the same group of women that
underwent diﬀerentiation in vitro in the presence of insulin,
dexamethasone, a methyl xanthine, and a thiazolidinedione.
In the data shown in Figure 2 the mRNA content of
freshly isolated omental fat cells versus in vitro diﬀerentiated
adipocytes was compared using total RNA as the recovery
standard as suggested by Bustin [94] since the expression of
cyclophilin A used as the recovery standard diﬀered signiﬁ-
cantlybetweenfatcellsandinvitrodiﬀerentiatedadipocytes.
The data indicate that many proteins are expressed at
far higher levels in adipocytes than in freshly isolated fat
cells. Some proteins that are expressed at higher levels in
adipocytesthaninfatcellsarenotenrichedinfreshlyisolated
fat cells as compared to nonfat cells (Figure 2). These are
shown in red and are: butyryl cholinesterase, haptoglobin,
apelin, PGC1α (peroxisome proliferator activator receptor-
γ coactivator 1α), ATR1 (angiotensin II receptor 1), αl
glycoprotein,endocannabinoidreceptor1,endothelin-1,and
omentin/intelectin.
Five mRNAs were found at comparable levels in
adipocytes as compared to fat cells. These were the β1
adrenergic receptor, 25-hydroxyvitamin D3 1α hydroxylase,
VEGF-a, ZAG, and lipin-1. Three genes were expressed at
lower levels in adipocytes than in fat cells: adipsin, insulin
receptor, and CIDEA. The data suggest that the one or
more of the added factors required for diﬀerentiation of
preadipocyes to adipocytes induce the expression of many
proteins that are not induced in vivo and decrease the
expression of others such as CIDEA and the insulin receptor.
Clearly the use of human adipocytes diﬀerentiated in vivo
from preadipocytes does not result in a pattern of gene
expression comparable to that seen in intact fat from obese
women.
6. Effect of Obesity on
InVitroAdipokine Release by
Explantsof HumanAdipose Tissue
Studies using freshly isolated explants preserve the cross talk
between the various types of cells in fat. However, since
the primary eﬀect of obesity is to increase adipose tissue
mass, it is diﬃcult to know how to express data obtained by
primary culture of human fat explants. How do you compare
total release by adipose tissue from humans with 20kg of
fat as compared to those with 40kg? In the studies shown
in Figure 3 release in vitro over a 48 hours incubation of
omental and subcutaneous fat from each woman per kg of
fat was multiplied by the total fat content. The women were
then divided by tertiles based on body fat content.
There was enhanced release of endothelin-1, lipocalin-2,
visfatin, GPX-3, and FABP-4 by the most obese women as
compared to that by women in the bottom tertile (Figure 3).8 Mediators of Inﬂammation
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The CIDEA mRNA ratio in omental
adipocytes to that in isolated fat cells
was 0.0024 indicating that it along with
the insulin receptor and adipsin are
preferentially expressed in freshly isolated
fat cells.
The red bars indicate those mRNAs that are
not preferentially expressed in isolated
human omental fat cells but are in
adipocytes diﬀerentiated in vitro.
(e)
Figure 2: Comparison of mRNA expression in isolated omental fat cells versus in vitro diﬀerentiated adipocytes. The data are shown as the
ratio of mRNA in human omental adipocytes, diﬀerentiated in vitro from the nonfat cells isolated from omental adipose tissue, to that in
freshly isolated fat cells obtained by collagenase digestion of omental adipose tissue from female bariatric surgery patients. The ratios were
derived from the Cp values and plotted on a log2 scale. Comparable amounts of total RNA were used for the mRNA analyses. The Cp values
from which the ratios were determined for fat cells were calculated from the data shown in Table 2 and for in vitro diﬀerentiated adipocytes
from Fain et al. [82, 83] or unpublished data. The red bars are for mRNAs whose expression in isolated fat cells was either the same or lower
than in isolated nonfat cells.Mediators of Inﬂammation 9
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Figure 3: The eﬀect of obesity on total release of 6 adipokines by explants of adipose tissue from obese women. The data are from the report
by Fain et al. [42] for release of 6 adipokines by adipose tissue from 22 women divided into tertiles. The lowest tertile was composed of 7
women with total fat masses of 18 to 40kg with a mean of 29kg. The middle tertile was composed of fat from 8 women with total fat masses
ranging from 41 to 52kg with a mean of 49kg. The highest tertile was fat from 7 women with fat masses ranging from 56 to 75kg (mean of
65kg). The ratio of total release by the highest tertile as compared to the lowest tertile is shown and all ratios were signiﬁcant with a P<. 001
except for zinc α2 glycoprotein [ZAG] release that was not statistically signiﬁcant (P>. 05).
For ZAG we found no eﬀect of obesity since total release
was not signiﬁcantly higher in women in the highest tertile
but they had 124% more fat than women in the lowest
tertile. Therefore there was actually decreased release per
g of adipose tissue. This is in agreement with reports that
gene expression of ZAG in fat is reduced in human obesity
[69, 70]. There was enhanced total release of intercellular cell
adhesion molecule 1 (ICAM-1), CD14, and LPL but not of
osteoprotegerin, RANTES or amyloid A [42].
Another way to examine the eﬀect of obesity is to
correlate total release with the total fat mass of each woman.
That resulted in a correlation coeﬃcient for lactate release
of 0.81 and for IL-8 release of 0.85 based on total release
plotted against the fat mass of each woman (Figure 4). A
positive correlation indicates that the more fat you have the
greater the total amount of lactate or IL-8, if release per g of
fat remains the same. In contrast, total amyloid and VEGF
release did not correlate with total fat mass indicating that
their release per g of tissue was less but the total release by fat
remained constant.
Data for 24 other adipokines are summarized in Table 3,
along with those for lactate, amyloid A, and VEGF and
IL-8 release shown in Figure 3. Adipokines that showed
no correlation, that is, those whose total release actually
decreased in obesity, were MCP-1, interleukin 1 receptor
antagonist 1 (IL1-Ra), adipsin, osteoprotegerin, RANTES,
ZAG, cathepsin S, vascular cell adhesion cell molecule 1
(VCAM-1) and NGFβ in addition to VEGF and amyloid A.
A number of inﬂammatory adipokines had a signiﬁcant cor-
relation between total release and total fat mass besides IL-
8 and these included, IL-10, transforming growth factor β1
(TGFβ1), visfatin, IL-1β, IL-6, CD14, endothelin-1, ICAM-
1, TNFα, lipocalin-2, PAI-1, and angiotensin 1 converting
enzyme (ACE) that are primarily released by the nonfat cells.
There was also a signiﬁcant correlation between total release
and fat mass for FABP-4, GPX-3, and LPL.
A problem complicating release studies by human fat is
that incubation in vitro induced an inﬂammatory response
as judged by enhanced mRNA accumulation over the 48
hours incubation for IL-8, IL-10, TGFβ1, visfatin, IL-1β,I L -
6, ICAM-1, TNFα, lipocalin-2, PAI-1 and ACE (Table 3).
Interestingly, an increase in mRNA expression over 48 hours
was seen for MCP-1, osteoprotegerin, and NGFβ whose
total release was not enhanced by obesity. Furthermore there
was no signiﬁcant change in the mRNA expression over
48 hours of CD14, endothelin-1 or ACE while there was a
marked decrease in FABP-4, GPX-3, and LPL mRNA but
enhanced release in obesity. These data suggest that the in
vitro inﬂammatory response does not mimic completely the
eﬀect of obesity.
In conclusion, adipose tissue from extremely obese
women, when incubated in vitro, releases more of a host
of adipokines such as IL-8, IL-10, TGFβ1, visfatin, IL-1β,
IL-6, ICAM-1, TNFα, lipocalin-2, PAI-1, and ACE than
does tissue from women with a lesser amount of fat. While
TNFα appears to be important it is one adipokine whose10 Mediators of Inﬂammation
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Figure 4: Correlation between total release of IL-8, VEGF, Amyloid A, and lactate by adipose tissue and total fat mass. The total release was
calculated by averaging release over 48 hours per kg by explants of visceral omental and subcutaneous adipose tissue from 14 [IL-8] or 22
diﬀerent women (lactate, amyloid A and VEGF) and multiplying by the total fat mass. Tissue samples were from the same women described
by Fain et al. [42]. The Pearson correlation coeﬃcients (r) are shown on the ﬁgure and the P value if statistically signiﬁcant with a P<. 05.
mRNA and release goes up transiently during in vitro
incubationofadiposetissue,butunlikeothermembersofthe
inﬂammatory cascade its release and gene expression return
to near basal values by 48 hours [61, 96].
7.WhichCellsintheNonfat
CellFraction Derivedfrom HumanAdipose
Tissue Are Responsible for Release of
InﬂammatoryAdipokines?
Hellmanetal.[97]reportedin1963thatobesityintheobese-
hyperglycemic mouse resulted in greater accumulation of
mast cells in white adipose tissue. They also pointed out
that the relative nitrogen content per gram of the epididymal
fat pad of the obese-hyperglycemic mouse was unchanged
despite the marked reduction in the number of fat cells per
g of tissue. Almost 40 years later Xu et al. [98]e x t e n d e d
this to show that the expression of genes enriched in murine
m a c r o p h a g e ss u c ha sM C P - 1 ,T N F α, CD68, and F4/80 was
elevated in obese mice. They also demonstrated that all of
these genes were preferentially expressed in the nonfat cells
of murine white fat [98]. Weisberg et al. [99] independently
published similar ﬁndings and emphasized that the size
of fat cells positively correlated with the percentage of
macrophages in murine adipose tissue.
Subsequently it was demonstrated that HAM56+ macro-
phage accumulation in visceral omental and subcutaneous
fat depots of humans also positively correlated with the
diameters of the fat cells in each depot. However, at any
fat cell size there were more macrophages in omental than
subcutaneous fat despite the fact that the average diameter of
subcutaneous fat cells was 40% greater than that of omental
fat cells [100]. The use of HAM56 as the macrophage marker
is important since in humans CD68 [101, 102], CD14 [102],
or F4-80 [102] are much less speciﬁc macrophage markers
than in mice. Similar results are shown in Table 2 in that
the gene expression of both CD14 and CD68 was not
signiﬁcantly diﬀerent between the fat cells and nonfat cells
isolated from human omental adipose tissue.Mediators of Inﬂammation 11
Table 3: Correlation between total release by explants of human fat and total fat mass as well as the change in mRNA over 48 hours
incubation.
Adipokine r value for correlation of release with fat mass Change in mRNA over 48 hour (ratio)
Those with signiﬁcant positive correlations of total release with fat mass
IL-8 0.85 510
Lactate 0.81
FABP-4 0.73 0.06
IL-10 0.70 13
TGFβ10 . 6 9 8
Visfatin 0.67 30
IL-1β 0.65 120
IL-6 0.65 675
CD14 0.64 1.7
Endothelin-1 0.63 1.4
sICAM-1 0.61 6.1
TNFα 0.59
GPX-3 0.56 0.33
Lipocalin-2 0.54 34
PAI-1 0.53 295
ACE 0.52 0.55
LPL 0.51 0.14
Those with no signiﬁcant correlations of total release with fat mass
Amyloid A 0.18 0.50
MCP-1 0.12 37
IL-1 Ra 0.10 9
Adipsin 0.01 0.23
Osteoprotegerin 0.01 4.9
VEGF −0.04
RANTES −0.05 1.2
Cathepsin S −0.07
ZAG −0.09 0.25
VCAM-1 −0.30
NGFβ −0.30 13
The values shown in bold are for adipokines whose gene expression was upregulated over the 48 hours incubation. The changes in mRNA as measured by
qRTPCR over 48 hours were based on comparison of unincubated adipose tissue explants with those after 48 hours and shown as the ratios derived from
the ΔCp values [95]. The Pearson correlation coeﬃcient (r) was derived by plotting the total release over 48 hours by the average of values for omental and
subcutaneous adipose tissue versus the calculated total fat mass in 20–22 obese women as described in Fain et al. [66–68]. The correlation coeﬃcients have
been published for TGFβ1[ 66], cathepsin S, nerve growth factor β (NGFβ), interleukin-1 receptor antagonist (IL-1Ra) and interleukin 18 (IL-18) [67]a s
well as those for adipsin, vascular cell adhesion molecule 1 (VCAM-1), and angiotensin1 converting enzyme (ACE) [68]. The correlation coeﬃcients for the
followingarederivedfromFainetal.[42]:endothelin-1,zinc-α2-glycoprotein(ZAG),lipocalin-2,CD14,RANTES,lipoproteinlipase(LPL),osteoprotegerin,
fatty acid binding protein 4 (FABP-4), visfatin, glutathione peroxidase-3 [GPX-3], intracellular cell adhesion molecule 1 [ICAM-1], and amyloid A while
those for IL-8, IL-6, PAI-1, TNFα, IL-10, VEGF, and IL-1β were derived from Fain et al. [62]. The changes in mRNA over 48 hours are from Fain et al. [95].
Thecurrentparadigmisthatobesityresultsinaccumula-
tionofmacrophagesinadiposetissueandtheseareprimarily
responsible for the release of inﬂammatory mediators [98–
100]. A relevant question is whether macrophages are the
only mononuclear phagocytes found in adipose tissue and
whether they account for all of the adipokine release by
nonfat cells. The potential contribution of the other nonfat
cells in human adipose tissue such as the endothelial cells of
the blood vessels, the smooth muscle cells and ﬁbroblasts as
well as other mononuclear phagocytes has not been carefully
examined.
Why do macrophages localize in the white adipose
tissue of obese animals? Whether enhanced lysis/death of
large fat cells is the primary trigger that accounts for
inﬂammation is unknown as well as what signal results in
greater macrophage accumulation in adipose tissue. One of
the functions of macrophages is to aid in the clearing of
dead cells. Cinti et al. [103] suggested that macrophages are
localized selectively to sites of necrotic-like cell death where
they appear as crown-like structures when viewed in tissue
sections. They also suggested that fat cell hypertrophy per se
promotes cell death resulting in macrophage accumulation
and aggregation around dead cells. The current paradigm is
that the larger the fat cell the more likely it is to undergo cell
death. However, a consistent ﬁnding is that human visceral
omental fat cells are smaller than subcutaneous fat cells12 Mediators of Inﬂammation
from the same individual but the macrophage accumulation
is greatest in omental fat so something besides fat cell
size is important [104]. Furthermore, thiazolidinediones
appear to selectively enhance the breakdown of large fat cells
in visceral omental fat resulting in smaller more insulin-
sensitive fat cells [105]. The net eﬀect of thiazolidinediones
is to preferentially enhance deposition of fat in subcuta-
neous adipose tissue while decreasing that in visceral fat
[105].
8. The RelativeExpression of mRNAs in Human
Epicardial,Substernal,Omental, Mesenteric,
andSubcutaneousAdipose Tissues
Currently it is thought that it is the increases in visceral
(intraperitoneal) rather than subcutaneous (extraperitoneal)
adipose tissue is linked to the enhanced risk of diabetes,
hypertension and cardiovascular disease in obesity [7–10].
Exactly how visceral adipose tissue is linked to this is unclear.
It could be due to greater release of inﬂammatory factors by
visceral fat or fatty acids and adipokines released by visceral
adipose tissue that are preferentially delivered to the liver
through the hepatic portal system.
The visceral fat is composed of omental and to a lesser
extent mesenteric adipose tissue. The search for a major
biochemicaldiﬀerencebetweenthesetwotypesofvisceralfat
and abdominal subcutaneous fat of extremely obese women
hasturnedupsomeinterestingdiﬀerencesingeneexpression
(Table 4).
The gene expression of UCP-1, omentin, and hap-
toglobin in subcutaneous fat was less than 10% of that
in omental fat. The data on UCP-1 conﬁrm the initial
report by Esterbauer et al. [107] that UCP-1 expression in
subcutaneous fat was 12% of that in omental fat. However,
the amount of UCP-1 gene expression, which is related to
thermogenesis, in epicardial fat of humans is at least 9-fold
greater than that in omental fat [106]. Sacks et al. [86]h a v e
postulated that the epicardial fat, which is located on the
outsideoftheheart,servestodefendthemyocardiumagainst
hypothermia.
Another protein whose gene expression was quite low
(about 1%) in subcutaneous as compared to omental fat
was omentin/intelectin (Table 4). It is also expressed at 3-
fold higher levels in epicardial fat than in omental fat [108].
Its preferential expression in intraperitoneal adipose tissue
probablyreﬂectsthefactthatthebloodvesselsinthesetissues
arise from endothelial cells of the gut during development
[108]. Unlike UCP-1, which is preferentially expressed in fat
cells of omental fat (Table 2), omentin/intelectin is primarily
found in the endothelial cells of the blood vessels [108].
It is unclear why haptoglobin is expressed at such low
levels in subcutaneous fat but its expression is also low in
mesenteric fat (Table 4). In contrast UCP-1 is found at the
same level of expression in mesenteric fat as in omental
fat while omentin/intelectin is found at far lower levels in
mesenteric than in subcutaneous fat. As for the low level of
expression of ATR2 in subcutaneous fat that is probably due
to overexpression of ATR1 in subcutaneous fat.
Comparison of mesenteric with omental fat indi-
cates that they have more in common with each other
than with subcutaneous fat. This is especially true with
regard to expression of UCP-1, prostaglandin D2 synthase,
angiotensinogen, ZAG, NFκB1,A T R 2, RBP-4, IL-6, and
osteopontin.
However, MCP-1, IL-1β, adrenomedullin, PPARγ,a n d
PAI-1 were expressed at signiﬁcantly lower levels in mesen-
teric than in omental fat while their expression in subcuta-
neous fat was the same as or higher than that in omental
fat. At this time these are simply lists of similarities and dif-
ferences between omental and mesenteric fat indicating that
theyarediﬀerenttissues.Itisalsonotyetestablishedwhether
the diﬀerences in mRNA expressionbetween omental and
mesenteric fat are in the fat or the nonfat cells. Furthermore
we know almost nothing about the physiological diﬀerences
in the metabolism and adipokine release of these two kinds
of intraperitoneal fat.
There have been many studies comparing the diﬀerences
in response of isolated fat cells derived from omental
as compared to subcutaneous fat and pieces of adipose
tissue from these depots [109, 110]. However, the data are
confusing since the results have been almost as varied as
the number of reports. This is especially true for PAI-1
gene expression and protein release. Some reported greater
in vitro release of PAI-1 by omental than by subcutaneous
fat [10], others no diﬀerence in gene expression or protein
content between omental and subcutaneous [111] while yet
another group reported greater release by subcutaneous than
omental adipose tissue from extremely obese humans [112].
This is a common occurrence in studies comparing omental
versussubcutaneousfatofhumansanditisunclearwhysuch
variable results are obtained.
The picture with regard to leptin gene expression and
release is equally controversial. While some groups have
reported greaterexpression and secretion by subcutaneous as
compared to omental fat [113, 114] another group reported
no diﬀerence [110] and a similar ﬁnding is in Table 4.
TNFα is one adipokine that is expressed (Table 4)a n d
released to the same extent by human omental and sub-
cutaneous adipose tissue [96, 115]. Another inﬂammatory
adipokine is lL-6 that is released at higher levels by omental
adipose tissue than by subcutaneous adipose tissue [62, 80]
but the gene expression of IL-6 was higher in freshly isolated
subcutaneous adipose tissue (Table 4).
Lipolysis is reported to be greater in adipoctyes derived
from subcutaneous than from visceral adipose tissue and
attributed to the greater size of the subcutaneous adipocyes
[116]. However, similar levels of expression for hormone
sensitive lipase (HSL) and perilipin have been reported
in subcutaneous as compared to omental adipose tissue
(Table 4, [117, 118]).
Giorgino et al. [109] have reviewed the evidence that fat
cells isolated from omental fat are more insulin-responsive
than those from subcutaneous human fat. Higher levels of
insulin receptor expression have also been seen in omental as
compared to subcutaneous adipose tissue [117, Table 4].
The visceral fat is composed of the intraperitoneal
omental and mesenteric in the peritoneal cavity as well asMediators of Inﬂammation 13
Table 4: Comparison of mRNAs in human mesenteric and subcutaneous as compared to omental adipose tissue from extremely obese
women.
mRNA subcutaneous as ratio of omental mesenteric as ratio of omental
mRNAs lower in both subcutaneous and mesenteric as compared to omental
Omentin/intelectin 0.01 ±0.01∗∗∗ 0.14 ±0.03∗∗∗
Angiotensin II receptor 2 [ATR2]0 .04 ±0.01∗∗∗ 0.35 ±0.10∗∗
Haptoglobin 0.08 ±0.01∗∗∗ 0.38 ±0.10∗∗∗
Nerve growth factor β [NGFβ]0 .22 ±0.02∗∗∗ 0.44 ±0.14∗∗
Complement factor C3 0.31 ±0.05∗∗∗ 0.47 ±0.08∗∗∗
VEGFR/FLT-1 0.41 ±0.09∗∗∗ 0.66 ±0.15∗
PGC-1α 0.41 ±0.14∗∗∗ 0.73 ±0.06∗∗
Insulin receptor 0.47 ±0.08∗∗∗ 0.44 ±0.14∗
SIRT1/sirtuin 1 0.47 ±0.15∗∗ 0.44 ±0.09∗∗∗
Collagen VI α30 .48 ±0.16∗∗ 0.60 ±0.11∗
mRNAs lower or higher in subcutaneous but not in mesenteric as compared to omental
Uncoupling protein1[UCP-1] 0.07 ±0.01∗∗∗ 1.23 ±0.60
Prostaglandin D2 synthase 0.27 ±0.05∗∗∗ 1.06 ±0.12
Angiotensinogen 0.33 ±0.04∗∗∗ 0.87 ±0.20
Bone morphogenetic protein 7 [BMP-7] 0.35 ±0.19∗∗ 1.02 ±0.16
Zincα2 glycoprotein [ZAG] 0.44 ±0.11∗∗∗ 0.83 ±0.06
NFκB1 [p50] 0.54 ±0.15∗ 0.81 ±0.19
CytochromeC oxidase 1.45 ±0.13∗∗∗ 1.10 ±0.13
Angiotensin II receptor 1 [ATR1]1 .62 ±0.18∗∗∗ 0.93 ±0.21
NAPDH oxidase [p67phox ]1 .90 ±0.22∗∗∗ 1.10 ±0.17
CD 14 2.30 ±0.37∗∗∗ 0.85 ±0.25
25-hydroxyvitamin D3 1α hydroxylase 3.00 ±0.64∗∗ 0.90 ±0.48
Retinolbindingprotein4[RBP-4] 3.10 ±0.26∗∗∗ 0.87 ±0.20
Interleukin 6 [IL-6] 3.50 ±0.55∗∗∗ 0.66 ±0.34
Osteopontin 4.90 ±0.51∗∗∗ 1.07 ±0.21
mRNAs lower or higher in mesenteric but not in subcutaneous as compared to omental
Monocyte chemoattractant protein 1 1.15 ±0.45 0.15 ±0.04∗∗
Interleukin 1β [IL-1β]0 .62 ±0.30 0.20 ±0.04∗∗∗
Adrenomedullin 0.97 ±0.09 0.38 ±0.13∗
PPARγ 1.23 ±0.15 0.44 ±0.11∗∗
β1 adrenergic receptor 1.00 ±0.07 1.74 ±0.27∗
mRNAs higher in subcutaneous and lower in mesenteric as compared to omental
Plasminogen activator inhibitor 1 1.62 ±0.27∗ 0.20 ±0.04∗∗∗
mRNAs higher in subcutaneous and mesenteric as compared to omental
α1g l y c o p r o t e i n 7 .00 ±0.86∗∗∗ 1.74 ±0. 27∗∗
mRNAs the same in subcutaneous and mesenteric as compared to omental (ratios were 0.50 to 1.50 of that in omental and not statistically signiﬁcant).
ACE, adiponectin, adipsin, amyloid A, cathepsin S, caveolin-1, CIDEA, CD68, cyclophilin, endothelin-1, FABP-4, FAT/CD36, Giα2, GPX-3, heme
oxygenase-1, HIF1α, 11β HSD-1, HSL, IL-8, leptin, lipocalin-2,L P L , NADPH oxidase [gp91phox], NGFβ [p65 RelA], eNOS, osteoprotegerin, perilipin,
PRDM-16, TNFα, Toll likereceptor 4,UCP-2, visfatin.
ThevalueswereobtainedbyqPCRasdescribedin[106]andareexpressedastheratio ±semof5to15pairedcomparisonsfromasmanydiﬀerentindividuals
of the amount of mRNA in mesenteric and subcutaneous fat as compared to omental fat from the same woman. The mRNAs enriched in fat cells by at least
3-fold are shown in bold. Statistically signiﬁcant diﬀerences are denoted as follows: ∗P ≥ .05, ∗∗P ≥ .01, and ∗∗∗P ≥ .005.
the intrathoracic fat depots of the substernal and epicardial
fat. The latter two fat depots diﬀer in that the epicardial
surroundstheheartwhilethesubsternalfatbodyisaseparate
tissue within the thoracic cavity. Gene expression in subster-
nal can be compared to that of epicardial fat to distinguish
possible diﬀerences between these two intrathoracic depots.
Fain et al. [106]f o u n dt h a to f4 5m R N A sa l le x c e p tﬁ v ew e r e
expressed in substernal fat at levels within 0.4 to 1.6-fold
of that in epicardial fat. These were haptoglobin (21-fold
greater), prostaglandin D2 synthase (6-fold greater), nerve
growth factor (5-fold greater), VEGFR/FLT1 (5-fold greater)
and α1 glycoprotein (2-fold greater) with greater expression
in epicardial as compared to substernal fat. UCP-1 is also
expressed at in epicardial fat at 5-fold higher amounts than14 Mediators of Inﬂammation
in substernal fat [86]. Of these only UCP-1 is expressed at
greater levels in fat cells than in the nonfat cells of human
omental adipose tissue (Table 2). These data are compatible
with the hypothesis that the fat cells in epicardial fat have
a unique function as a brown fat-like tissue and could be
involved in thermogenesis.
Epicardial fat has been postulated to be an inﬂammatory
organ releasing adipokines that contributes to coronary
artery disease because of the unique anatomical relation-
ship between this fat and the coronary arteries [119].
However, when the gene expression of IL-6, IL-1β, PAI-
1 or cyclooxygenase-2 was compared in epicardial fat of
patients undergoing coronary artery bypass surgery to that
in obese individuals undergoing gastric bypass surgery their
expression in epicardial fat was less than 25% of that in
omental fat [106]. It could be argued that this was because
the bypass patients diﬀered in other aspects, which they
did, but the expression of 20 other protein ranged from
0.4 to 1.3 in omental fat to that seen in epicardial fat. In
contrast, signiﬁcantly higher amounts (1.6 to 2-fold greater)
of the insulin receptor, ZAG, leptin, angiotensinogen and
LPL were expressed in epicardial fat as compared to that
in omental fat [106]. The signiﬁcance of these diﬀerences
between epicardial and omental fat remains unclear but do
not suggest that epicardial fat is more inﬂamed than omental
fat.
In conclusion, the reported diﬀerences in gene expres-
sion, hormonal sensitivity, and release of adipokines by
visceral as compared to subcutaneous adipose tissue have
been almost as varied as the number of reports [109, 110].
Furthermore, they provide few clues that can explain the
putative harmful eﬀect of enhanced accumulation of visceral
fat. The fat cells found in visceral fat are smaller than those
of subcutaneous fat from obese individuals but is that due to
greater breakdown of large fat cells in visceral fat?
There are clear diﬀerences between mesenteric and
omental fat but again it is unclear what they represent.
Comparisons of visceral omental versus subcutaneous fat
are probably inﬂuenced by the degree of obesity and this
was demonstrated for PPARγ where the ratio in visceral
to subcutaneous was around 0.2 at a body mass index
of 20 but increased to about 1.2 in individuals with a
body mass index of 50 [117]. Future studies will require
the development of procedures to accurately assess the
gene expression and release of adipokines by the diﬀerent
human adipose tissue depots under more physiological and
reproducible conditions.
Recently the microRNA (miRNA) proﬁles of human
omental and subcutaneous have been compared in humans
without or with diabetes [120]. The expression of 155
miRNAswasexaminedandsomediﬀerenceswerefoundthat
were said to correlate with fat cell phenotype, obesity, and
glucose metabolism [120]. However, no miRNA was found
exclusively in one fat depot versus the other suggesting a
common developmental proﬁle [120].
I conclude that the gene expression proﬁle of omental
fat clearly diﬀers from that of subcutaneous fat for some
proteins. However, none of these diﬀerences appear to
explain the putative harmful eﬀects of visceral obesity.
Furthermore, there is scant agreement in the literature with
respect to most proteins. This is possibly due to small sample
sizes, sex diﬀerences, age diﬀerences, the extent of obesity,
and the disease status of the humans from whom fat samples
were obtained. For ethical reasons samples of omental and
subcutaneous fat cannot be obtained from healthy donors.
Mostsamplesofhumanomentalfathavebeenobtainedfrom
individuals undergoing gallstone, gynecological, or bariatric
surgery. While individuals healthy enough to undergo
bariatric surgery are extremely obese, the normal weight
individuals always have some underlying disease process that
could aﬀect gene expression and adipokine release.
9.What Is the LinkbetweenTLR-4, Enlarged
FatCells,andthe Inﬂammatory Response
Seen inObese Humans
Recentlythetoll-likereceptor4(TLR-4),thatplaysanimpor-
tant role in innate immunity through its ability to recognize
bacterial lipopolysaccharides, has been postulated to play a
role in the obesity-induced inﬂammatory response [95, 121,
122]. A loss-of-function mutation in TLR-4 prevents diet-
induced obesity in mice and the development of insulin
resistance[95,121].Inmacrophagesandculturedadipocytes
potent inducers of TLR-4 gene expression are bacterial
lipopolysaccharides resulting in the release of inﬂammatory
adipokines [123, 124]. In a monocyte/macrophage cell line
(RAW 264.7) saturated, but not unsaturated fatty acids,
induced the expression of COX-2 expression via TLR-4
[123]. Schaeﬄer et al. [122] reported that saturated fatty
acids could induce the secretion of MCP-1 and other inﬂam-
matory adipokines in murine 3T3L1 adipokines through a
pathway involving TLR-4.
Lin et al. [124] originally suggested that a fully
intact pathway of innate immunity was present in rodent
adipocytes that could be activated by bacterial lipopolysac-
charides. Subsequently, functional TLR-4 has been found in
human fat cells [125, 126] and the data in Table 2 indicates
that in human omental fat the gene expression of TLR-4 is
5-fold greater in fat cells than in the nonfat cells. Zha et
al. [127] reported that in vitro diﬀerentiated adipocytes had
more TLR-4 mRNA than did preadipocytes and that TNFa
secretion was induced by free fatty acids. My laboratory
has similar ﬁndings in that the TLR-4 mRNA expression
in human omental adipocytes diﬀerentiated in vitro was
also 5-fold higher than that in preadipocytes (John N.
Fain, unpublished experiments). In omental adipose tissue
explants incubated for 48 hours TLR-4 gene expression
was down regulated by about 70% but this was blocked
in the presence of dexamethasone [128]. This may reﬂect
a down-regulation of TLR-4 secondary to the 90 to 700-
fold activation of the expression of inﬂammatory cytokines
such as I-8, IL-6 and IL-1β that was markedly inhibited by
dexamethasone [128].
It has been suggested that the hypertrophied fat cells
seen in extreme obesity release large amounts of satu-
rated fatty acids secondary to macrophage-induced lipolysis
occurring in fat cells [129] .T h e r ei se v i d e n c ei nr o d e n tMediators of Inﬂammation 15
adipocytes that bacterial lipopolysaccharides can stimulate
lipolysis via TLR-4 [130]. However, addition of bacterial
lipopolysaccharides to explants of human adipose tissue
incubated for 48 hours enhanced release of IL-1β,I L - 6 ,a n d
IL-8 by 50% to 70% under conditions where there was no
signiﬁcant increase in lipolysis (John N. Fain, unpublished
experiments). Possibly breakdown of hypertrophied fat cells
could be the primary trigger for the inﬂammatory response
via activation of TLR-4 by fatty acids in neighboring intact
fat cells resulting in the release of inﬂammatory adipokines
that cause monocyte recruitment into the adipose tissue
and insulin-resistance. However, this hypothesis is probably
an over-simpliﬁcation since thiazolidinediones appear to
enhance the breakdown of large fat cells and the accumu-
lation of small fat cells but this is associated with enhanced
insulin sensitivity [105].
It was surprising to ﬁnd TLR-4, whose function has
traditionally been thought of as being involved in pathogen-
associated molecular recognition by immune cells, expressed
at higher levels in fat cells than in nonfat cells in human
fat cells. The physiological function, if any, of this enhanced
expression remains to be elucidated. Another unanswered
question is what is the primary trigger that results in the
accumulation of activated macrophages in the adipose tissue
of extremely obese humans?
10. Hypoxiaas the PrimaryTrigger of
the Inﬂammatory Response
This hypothesis was originally proposed in 2004 by Trayhurn
andWood[1]anddiscussedinrecentarticles[131–134].The
best evidence for the “hypoxia hypothesis” is the evidence
that adipose tissue is poorly oxygenated in the obese [134,
135]. The mechanisms involved are not understood beyond
theacceptedparadigmthatHIF1αactivationoccursresulting
in activation of NFκB leading to increased gene transcription
of inﬂammatory adipokines. Yin et al. [133] recently sug-
gested that hypoxia in adipose tissue activates lipolysis and
inhibits fatty acid uptake by adipocytes leading to activation
of an inﬂammatory response via TLR-4. There is no evidence
that activation of lipolysis per se induces an inﬂammatory
response in human fat. Fain et al. [136] reported that growth
hormone in the presence of dexamethasone, but not in its
absence, stimulated lipolysis by explants of human omental
adipose tissue over a 48 hours incubation but this was
not accompanied by an increase in IL-8 gene expression or
release.
Another problem is that while there is evidence that
the adipose tissue from the ob/ob mouse is hypoxic in
comparison to fat from obese mice, there was no increase
in expression of VEGF while there was of hypoxia response
g e n e ss u c ha sH I F - 1 α, IL-6, Il-1β,a n dT N F α [134]. A
similar ﬁnding has been reported by Halberg et al. [137]a n d
remains to be explained since the current paradigm is that
hypoxic tissues release VEGF that leads to increased tissue
vascularization. However, the hypothesis may be incorrect or
angiogenesis may also require other, as yet unknown, factors.
An attractive hypothesis is that as fat cells expand there
is insuﬃcient neovascularization to keep the cells from
becoming hypoxic. This results in activation of HIF1α and
a variety of responses including increased formation of
inﬂammatory adipokines as well as activation of collagen
synthesis and crosslinking of collagen involving lysyl oxidase
[137]. There is global upregulation of extracellular matrix
formation that hampers oxygen access to the cells and the
increased stress resulting from expansion of the fat cells
resulted in rupture of very large cells [137]. The fatty acids
resulting from breakdown of triacylglycerols released by
rupturedfatcellscouldactivatemacrophagesaswellasintact
fat cells.
Alternatively, hypoxia leads to the death of large fat
cells and macrophages are drawn to areas of recent cell
death by mediators still to be described that are released
after cell death, as suggested by Rausch et al. [135]. It may
well be that visceral omental fat cells are more liable to
lysis which explains why these fat cells are smaller than
those found in subcutaneous adipose tissue. Furthermore it
is commonly accepted, but may be an over-simpliﬁcation,
that visceral adipose tissue has more macrophages than
subcutaneous adipose tissue and releases more inﬂamma-
tory adipokines. Explants, but not isolated fat cells, of
o m e n t a la d i p o s et i s s u eh a v eb e e ns h o w nt or e l e a s em o r e
PGE2, PAI-1, IL-6, and VEGF than abdominal subcutaneous
adipose tissue on a per g basis [62]. Similar results have
been reported for IL-8 content of and release by visceral
omental as compared to subcutaneous human adipose tissue
[138].
11. Summary
The data in Figure 5 summarizes the relative release of
selected adipokines by fat cells and nonfat cells of human
adipose tissue. Of the adipokines shown in the ﬁgure only
leptin, FABP-4, GPX-3, and adiponectin are expressed at 5 to
80-fold higher levels in fat cells than the other cells present
in human fat and primarily released by fat cells. Adiponectin
and GPX-3 are listed in blue because their circulating levels
are lower in obesity.
The adipokines with black lettering are those whose
circulating levels are enhanced in obesity and whose total
release by adipose tissue explants is enhanced in obesity: IL-
6, IL-10, ACE, TGFβ1, ICAM-1, TNFα,I L - 1 β, PAI-1, and
IL-8 that are released by nonfat cells. However IL-10 may
be an anti-inﬂammatory adipokine primarily released by the
nonfat cells, whose circulating levels as well as in vitro release
are elevated in obesity. The release of leptin and FABP-4
by fat cells is also enhanced in human obesity. It should be
understood that most of these adipokines act locally and
whether the changes in circulating levels of adipokines seen
in obesity reﬂect release by adipose or other tissues remains
to be established.
Omentin/intelectin is a novel adipokine preferentially
found in visceral fat depots, especially human epicardial fat
whose site of origin is the endothelial cells of blood vessels.
For this reason it is listed in Figure 5 as being derived from
the endothelial cells in the vessel wall. In conclusion, most
of adipokines whose circulating levels are elevated in obesity
and whose release by human adipose tissue is enhanced in16 Mediators of Inﬂammation
IL-6
IL-10
ACE
TGFβ1
TNFα
ICAM-1
PAI-1
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Figure 5:Therelationshipbetweenadipokinereleaseandparacrine
signaling in human adipose tissue. The adipokines are divided
into those released by fat cells [leptin, FABP-4, adiponectin, and
GPX-3] and those by nonfat cells in adipose tissue [IL-6, IL-8, IL-
10, ACE, PAI-1, ICAM-1, TNFα,T G F β1, and omentin/intelectin].
Adipokines shown in black are those whose circulating levels are
elevated in obesity as well as their release by incubated human
adipose tissue explants. Circulating levels of adiponectin and GPX-
3 are shown in blue since they are not elevated in obesity.
Omentin/intelectin is shown as being secreted by the endothelial
cells of the blood vessels of omental but not subcutaneous fat
[108]. The arrows depict possible targets of the adipokines as the
other cells in adipose tissue, as well as vascular smooth muscle cells
(VSMC) and endothelial cells in the blood vessel walls plus release
into the circulation (lumen of blood vessel).
obesity are inﬂammatory adipokines primarily derived from
the nonfat cells of human adipose and other tissues.
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